SpliceBio raises €50M Series A round co-lead by UCB Ventures and Ysios, and also backed by New Enterprise, Gilde, NovartisVF and Asabys

Inversión, Venture Capital

16/02/2022 Nota de prensa SPLICEBIO RAISES €50M IN OVERSUBSCRIBED SERIES A FINANCING TO ADVANCE PROTEIN SPLICING PLATFORM AND EXPAND GENE THERAPY PIPELINE.         • Financing co-led by UCB Ventures and Ysios Capital with participation by New Enterprise Associates, Gilde Healthcare, Novartis Venture Fund and Asabys Partners • Unique Protein Splicing platform enables…

SpliceBio cierra una ronda Series A de €50M coliderada por UCB Ventures e Ysios. Acuden también New Enterprise, Gilde Healthcare, NovartisVF y Asabys Partners

Inversión, Venture Capital

16/02/2022 Nota de prensa SPLICEBIO CIERRA UNA RONDA SERIES A DE €50M PARA AVANZAR CON EL DESARROLLO DE SU PLATAFORMA DE PROTEIN SPLICING Y EXPANDIR SU PIPELINE DE TERAPIA GÉNICA.       • La ronda ha sido coliderada por UCB Ventures e Ysios Capital y ha contado con la participación de New Enterprise Associates,…